GlucoSet's critical care monitoring solutions enable clinics to reduce complications and cost. The company's real-time, intra-vascular, hydrogel-based continuous glucose monitor delivers constant accurate information on blood glucose levels, making continuous glucose control in the ICU a reality.
Total raised: $6.54M
Investors 2
| Date | Name | Website |
| 11.11.2023 | Serpentine... | serpentine... |
| - | Swiss Diab... | diabetesfu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.07.2023 | Series A | $6.54M | - |
Mentions in press and media 3
| Date | Title | Description |
| 07.07.2023 | Medtech startup GlucoSet raises €6M in series A | GlucoSet - intensive care monitoring GlucoSet secured over €9M in dilutive and non-dilutive funding in the first closing of its series A round, led by the Swiss Diabetes Venture Fund This first closing of the series A reduces our risk signi... |
| 05.11.2021 | First edition of the DCB Innovation Challenge successfully completed | |
| - | GlucoSet | “GlucoSet develops tools for accurate continuous glucose monitoring in Intensive Care Units, to reduce patient mortality and hospital costs.” |